Charles River Laboratories Signs Licensing Agreement with Luminex(R) Corporation

The Luminex xMAP technology enables multiple assays to beperformed in a single well, or multiplexed, utilizing suspendedmicrospheres or beads. Up to 100 different simultaneous assays can beperformed in a single microtiter well, both rapidly and precisely.Charles River's Research Animal Diagnostic Services division will usethe technology to create the Multiplexed Fluorometric ImmunoAssay(MFIA), which will be adopted as the platform for screening laboratoryanimal serum samples for infectious disease.

William Barbo, Charles River Laboratories Corporate VicePresident, Research Model Services, said, "Charles River is pleased tojoin Luminex in this licensing agreement. The use of Luminex's xMAPtechnology in the form of MFIA will allow us the flexibility tofurther refine and expand our assays, delivering unparalleled productsand services in the area of laboratory animal diagnostics."

Russell Bradley, Vice President of Business Development andStrategic Planning, Luminex Corporation, said, "We are pleased CharlesRiver Laboratories has selected our xMAP technology as their multiplexplatform of choice for the standardization of animal diagnosticassays. As a market leader, Charles River Laboratories joins a growingteam of Luminex partners bringing the benefits of Luminex's bead basedmultiplexing to their customers."

About Charles River Laboratories

Charles River Laboratories, based in Wilmington, Massachusetts,U.S., is a global provider of solutions that advance the drugdiscovery and development process. Our leading-edge products andservices are designed to enable our clients to bring drugs to marketfaster and more efficiently. Backed by our rigorous, best-in-classprocedures and our proven data collection, analysis and reportingcapabilities, our products and services are organized into threecategories spanning every step of the drug development pipeline:Research Models and Services, Preclinical Services, and ClinicalServices. Charles River's customer base includes all of the majorpharmaceutical companies and many biotechnology companies, governmentagencies and leading hospitals and academic institutions. CharlesRiver's 8,400 employees serve clients in more than 50 countries. Formore information on Charles River, visit our website atwww.criver.com.

About Luminex(R) Corporation

Luminex Corporation develops, manufactures and markets proprietarybiological testing technologies with applications throughout the lifesciences industry. The Company's xMAP system is an open-architecture,multi-analyte technology platform that delivers fast, accurate andcost-effective bioassay results to markets as diverse aspharmaceutical drug discovery, clinical diagnostics and biomedicalresearch, including the genomics and proteomics research markets. TheCompany's xMAP technology is sold worldwide and is in use in leadingresearch laboratories as well as major pharmaceutical, diagnostic andbiotechnology companies. Luminex's xMAP technology received the 2005Clinical Diagnostics Technology of the Year Award from Frost &Sullivan. Further information on Luminex Corporation or xMAP can beobtained on the Internet at http://www.luminexcorp.com or you maycontact Harriss T. Currie, Chief Financial Officer of LuminexCorporation, +1-512-219-8020.